Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DermNPPa
- Ownership
- Private
- Development stage
- Other
01
Overview
DermNPPa is a preclinical-stage biotechnology company focused on developing novel peptide-based therapeutics for inflammatory skin diseases and chronic pruritus. The company's lead candidate, DermNPPa, is a synthetic analog of Natriuretic Peptide A (NPPa) designed to target the NPR1 receptor to modulate neuro-inflammatory pathways in the skin. By leveraging a proprietary nanoparticle delivery system, the company aims to provide localized, long-acting relief for conditions like atopic dermatitis without the systemic side effects associated with traditional immunosuppressants. DermNPPa is currently advancing its lead program through IND-enabling studies.
- Therapeutic areas
- Dermatology
- Modalities
- PeptideBiologicNanoparticle
- Industry
- Biotech
Beyond the preview
Go deeper on DermNPPa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DermNPPa.